Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

HOERSHOLM, Denmark and SAN DIEGO, April 26 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

High cholesterol is a major risk factor for coronary heart disease, heart attack and stroke. According to the World Health Organization, high cholesterol is estimated to cause 18% of strokes and 56% of heart disease, globally and amounts to approximately 4.4 million deaths and 40.4 million disability-adjusted life years(1).

Santaris Pharma A/S presented preclinical data on SPC5001 last month at the PCSK9 Conference "From gene to therapeutics" in Nantes, France where many top pharmaceutical companies gathered to discuss efforts to develop therapies aimed at inhibiting the important new target PCSK9, a protein involved in regulating LDL (low-density lipoprotein) or "bad" cholesterol in the blood.

Data presented by Santaris Pharma A/S scientists showed that SPC5001 provided potent, specific and long-lasting inhibition of PCSK9 and lowered mean LDL cholesterol by 50% in non-human primates with a sustained reduction of 74% in the highest responder. SPC5001 did not change HDL (high-density lipoprotein) levels or the "good" cholesterol in the blood(2). The preclinical data suggest that SPC5001 has the potential to provide patients with a new treatment opti
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... One of the most extensive, widely cited ... is now available to high school and junior college students ... the international society for optics and photonics , announced today ... Digital Library available to high schools for free and ... integral to all areas of life in today’s world,” said ...
(Date:11/24/2014)... 24, 2014 Senior Vice President, ... dynamic leadership skills, business acumen Elsevier ... information products and services, congratulates Diane Bartoli , ... and Workflow, Elsevier Clinical Solutions, for being recognized in ... Awards issue of Profiles in Diversity Journal ...
(Date:11/22/2014)... 21, 2014 CannLabs, Inc. ... analytics and scientific testing methodologies relating to cannabis, today ... $750,000 line of credit from an existing stockholder of ... have secured this commitment from one of our existing ... CannLabs. “This capital will help accelerate our planned expansions ...
(Date:11/22/2014)...  The element of surprise has been a major ... without warning. Until now, epidemiologists had nothing to measure ... resulting in suboptimal responses to both the H1N1 pandemic ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 That ... virus gene structural changes have been found that invariably ...
Breaking Biology Technology:SPIE Digital Library Now Available to High Schools, Two-Year Colleges at No or Low Cost 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3CannLabs Secures $750,000 Line Of Credit 2Viruses' Advantage of Surprise is Lost 2
... , , , ... ADL), a US-based pharmaceutical company with major assets in China, announced today ... of the Company as " Radient Pharmaceuticals Corporation" . ... will be "RPC" . The Company has filed an ...
... , SEATTLE, Sept. 18 Omeros Corporation ... 6.82 million shares of its common stock. Omeros is ... products focused on inflammation and disorders of the central nervous ... for the initial public offering is $10.00 to $12.00 per ...
... , , SAN MATEO, ... a biopharmaceutical company focused on developing and commercializing novel pain management ... is scheduled to present at the UBS Global Life Sciences Conference, ... City. , , Mr. DiTonno and Stephen ...
Cached Biology Technology:AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 2AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 3AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 4AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US 5Omeros Commences Initial Public Offering of Common Stock 2Omeros Commences Initial Public Offering of Common Stock 3NeurogesX to Present at UBS Global Life Sciences Conference 2NeurogesX to Present at UBS Global Life Sciences Conference 3
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
(Date:11/7/2014)... associate professor, biomedical engineering, in the Grove School ... York, have identified a molecule that could lead ... aggressive forms of breast cancer. , Triple negative ... owing to aggressive proliferation and metastasis and a ... team, discovered the overexpression of intercellular adhesion molecule-1 ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... recorded during a record-setting expedition have yielded new insights ... in the cold, dark, and highly pressurized habitats of ... Natalya Gallo of Scripps Institution of Oceanography at ... DEEPSEA CHALLENGE expedition, a project led by James Cameron ...
... his doctoral student Nicole Bance are among an international group ... compounds capable of killing the influenza virus. , Working ... can be a killer, the scientists have advanced previous researchers, ... influenza replicates and spreads. , Their new compounds will ...
... 21, 2013) Cardiovascular disease specialists at Florida Hospital Pepin ... with the University of South Florida announced they have enrolled ... gene therapy for the treatment of heart failure after ischemic ... tissue by encouraging the body to deploy more stem cells ...
Cached Biology News:Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals 2Vibrant mix of marine life found at extreme ocean depths, Scripps analysis reveals 3Influenza study: Meet virus' new enemy 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 3
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,669-3) ... assistance. ID clarifier: barcoded Mfr ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Biology Products: